کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3944932 1254242 2012 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Impact of beta blockers on epithelial ovarian cancer survival
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی زنان، زایمان و بهداشت زنان
پیش نمایش صفحه اول مقاله
Impact of beta blockers on epithelial ovarian cancer survival
چکیده انگلیسی

ObjectiveStress may promote ovarian cancer progression through mechanisms including autonomic nervous system mediators such as norepinephrine and epinephrine. Beta blockers, used to treat hypertension, block production of these adrenergic hormones, and have been associated with prolonged survival in several malignancies. We sought to determine the association between beta blocker use and epithelial ovarian cancer (EOC) disease progression and survival.MethodsWe performed an institutional retrospective review of patients with EOC treated between 1996 and 2006. Patients underwent cytoreductive surgery followed by platinum-based chemotherapy. Women were considered beta blocker users if these medications were documented on at least two records more than 6 months apart. Statistical tests included Fisher's exact, Kaplan–Meier, and Cox regression analyses.Results248 met inclusion criteria. 68 patients used antihypertensives, and 23 used beta blockers. Median progression-free survival for beta blocker users was 27 months, compared with 17 months for non-users (p = 0.05). Similarly, overall disease-specific survival was longer for beta blocker users (56 months) compared with non-users (48 months, p = 0.02, hazard ratio = 0.56). Multivariate analysis identified beta blocker use as an independent positive prognostic factor, after controlling for age, stage, grade, and cytoreduction status (p = 0.03). Overall survival remained longer for beta blocker users (56 months) when compared with hypertensive patients on other medications (34 months) and patients without hypertension (51 months) (p = 0.007).ConclusionsIn this cohort of patients with EOC, beta blocker use was associated with a 54% reduced chance of death compared with that of non-users.


► We predict that beta blocker use correlates with improved outcome in ovarian cancer.
► We retrospectively evaluated the association between beta blocker use and survival.
► Beta blocker use was associated with improved progression-free and overall survival and was an independent positive prognostic factor.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Gynecologic Oncology - Volume 127, Issue 2, November 2012, Pages 375–378
نویسندگان
, , ,